Visionary startups developing innovative life science technologies with outsized potential often struggle to raise capital from traditional funders. These companies are typically multi-disciplinary (e.g. genomics + optics + microfluidics + big data) and/or market-making, and don't neatly fit most VC’s patterns and boxes.
Genoa Ventures stands in this gap. Genoa Ventures uniquely combines an appetite for technology-driven, “category-defying” opportunities in life sciences with the domain expertise and operational experience necessary to select and nurture the best bio-based companies early, before most other investors. We take the time to understand the science and technology, applications and markets, and to help these companies achieve their full potential.
We believe in the enormous and relatively untapped possibilities of life science technologies and discoveries applied to realms outside of healthcare, and in the unbounded potential of the entrepreneurial visionaries who will lead us in realizing these possibilities.
Life Science Expertise
Experienced investors with deep domain expertise
Seed, Series A, and follow-on
We bring a builder mindset
It’s your ship; we’ll help you get there faster
Areas We Invest In
Genoa Ventures invests in early-stage life sciences companies innovating at the intersection of biology, technology, and data science. From next-gen 'omics platforms to CRISPR-Cas genome editing, our portfolio companies are transforming biomedical research, diagnostics, agriculture, chemicals, and other industries beyond traditional biotech therapeutics.
Technology Driving Biology
Miniaturization, automation, data sciences
Biology as Technology
Synthetic biology, genetic engineering, stem cells
Biology Beyond Healthcare
Agriculture, chemicals/industrial, consumer
Jenny Rooke PhD
Founder, Managing Director
A decade of investing experience in life sciences and deep tech
For over a decade, Genoa Ventures’ founder and managing director Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function.
In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns.
William C. Hyun MS, hPhD
Scientist, inventor, entrepreneur, and strategic investor
With more than 25 years of life technology experience, William (Bill) Hyun is a respected expert in both basic research and clinical technology development. At the University of California San Francisco, he directed one of the largest academic core laboratories in the world, with a strong concentration on cytometry and genomic technologies and applications. His academic career included joint appointments at UC Berekeley and the Lawrence Berkeley National Lab, three honorary doctorates, and authorship of over 100 peer-reviewed publications. Bill has been has been directly involved in the conception, design, and engineering of numerous commercially successful analytical instruments, consumables products, and software programs.
Bill's career is characterized by his ability to repeatedly identify opportunities for disruptive science and technology in transformative markets, and to add value through the life cycle of a start-up. Bill has been a founder, investor, and/or advisor to more than 20 startups with the common goal of impacting healthcare worldwide. Bill has served as Venture Partner with two Bay Area venture groups focused on early-stage investment, and is closely affiliated with four life tech incubators.